- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...

NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating ...

Risankizumab (Skyrizi) was effective for treating psoriatic arthritis (PsA) in patients who did not respond to or who could not tolerate other biologics or standard disease-modifying antirheumatic ...

A medicine licensed to treat psoriasis worsened symptoms in patients with severe asthma, according to trial results. A medicine licensed to treat psoriasis worsened symptoms in patients with severe ...

LAS VEGAS, Nevada — Risankizumab (Skyrizi) provides early and lasting benefits for patients with Crohn's disease, phase 3 trials indicate. Based on these and other recent findings, the drug could be ...

NORTH CHICAGO, Ill., Aug. 28, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and ...

In a post-hoc analysis of the ADVANCE and MOTIVATE phase III induction studies, along with the FORTIFY maintenance study, researchers evaluated the safety profile of risankizumab (Skyrizi) in patients ...

Risankizumab, a biologic, is used for psoriasis, but whether it can improve asthma control has been unclear. A study released Thursday in The New England Journal of Medicine of risankizumab for the ...

The FDA has approved risankizumab (Skyrizi), an interleukin (IL)-23 inhibitor, for the treatment of moderately to severely active Crohn's disease, AbbVie announced on Friday. The approval for Crohn's ...